Biomarker-Assisted Dose Selection for Safety and Efficacy in Early Development of PNU-100480 for Tuberculosis
Open Access
- 1 February 2011
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 55 (2), 567-574
- https://doi.org/10.1128/aac.01179-10
Abstract
Tuberculosis is a serious global health threat for which new treatments are urgently needed. This study examined the safety, tolerability, pharmacokinetics, and pharmacodynamics of multiple ascending doses of the oxazolidinone PNU-100480 in healthy volunteers, using biomarkers for safety and efficacy. Subjects were randomly assigned to PNU-100480 or placebo (4:1) at schedules of 100, 300, or 600 mg twice daily or 1,200 mg daily for 14 days or a schedule of 600 mg twice daily for 28 days to which pyrazinamide was added on days 27 and 28. A sixth cohort was given linezolid at 300 mg daily for 4 days. Signs, symptoms, and routine safety tests were monitored. Bactericidal activity against Mycobacterium tuberculosis was measured in ex vivo whole-blood culture. Plasma drug and metabolite concentrations were compared to the levels required for inhibition of M. tuberculosis growth and 50% inhibition of mitochondrial protein synthesis. All doses were safe and well tolerated. There were no hematologic or other safety signals during 28 days of dosing at 600 mg twice daily. Plasma concentrations of PNU-100480 and metabolites at this dose remained below those required for 50% inhibition of mitochondrial protein synthesis. Cumulative whole-blood bactericidal activity of PNU-100480 at this dose (−0.316 ± 0.04 log) was superior to the activities of all other doses tested ( P < 0.001) and was significantly augmented by pyrazinamide (−0.420 ± 0.06 log) ( P = 0.002). In conclusion, PNU-100480 was safe and well tolerated at all tested doses. Further studies in patients with tuberculosis are warranted. Biomarkers can accelerate early development of new tuberculosis treatments.Keywords
This publication has 29 references indexed in Scilit:
- Pharmacokinetics and Whole‐Blood Bactericidal Activity againstMycobacterium tuberculosisof Single Doses of PNU‐100480 in Healthy VolunteersThe Journal of Infectious Diseases, 2010
- Survival and Replication of Clinical Mycobacterium tuberculosis Isolates in the Context of Human Innate ImmunityInfection and Immunity, 2005
- Lack of Activity of Orally Administered Clofazimine against IntracellularMycobacterium tuberculosisin Whole-Blood CultureAntimicrobial Agents and Chemotherapy, 2004
- Bactericidal and Sterilizing Activities of Antituberculosis Drugs during the First 14 DaysAmerican Journal of Respiratory and Critical Care Medicine, 2003
- Whole Blood Bactericidal Activity during Treatment of Pulmonary TuberculosisThe Journal of Infectious Diseases, 2003
- The curious characteristics of pyrazinamide: a review.2003
- In Vitro Activities of Linezolid against Clinical Isolates of Mycobacterium tuberculosis That Are Susceptible or Resistant to First-Line Antituberculous DrugsAntimicrobial Agents and Chemotherapy, 2003
- A Whole Blood Bactericidal Assay for TuberculosisThe Journal of Infectious Diseases, 2001
- Activities of Several Novel Oxazolidinones against Mycobacterium tuberculosis in a Murine ModelAntimicrobial Agents and Chemotherapy, 1999
- Identification of a Novel Oxazolidinone (U-100480) with Potent Antimycobacterial ActivityJournal of Medicinal Chemistry, 1996